Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn

Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to ... Read More